REVOLUTION Medicines

REVOLUTION Medicines

RVMD

Revolution Medicines is a publicly-traded precision oncology company dedicated to revolutionizing cancer treatment through targeted therapeutics. The company leverages advanced drug discovery capabilities to develop novel medicines for patients with limited treatment options. With a focus on precision medicine approaches, Revolution Medicines aims to transform outcomes for cancer patients through innovative therapeutic solutions.

RVMD · Stock Price

USD 94.29+56.19 (+147.48%)
Market Cap: $18.8B

Historical price data

AI Company Overview

Revolution Medicines is a publicly-traded precision oncology company dedicated to revolutionizing cancer treatment through targeted therapeutics. The company leverages advanced drug discovery capabilities to develop novel medicines for patients with limited treatment options. With a focus on precision medicine approaches, Revolution Medicines aims to transform outcomes for cancer patients through innovative therapeutic solutions.

OncologyPrecision Medicine

Technology Platform

Proprietary drug discovery platform focused on developing targeted therapies that outsmart cancer mechanisms through precision oncology approaches.

Pipeline

14
14 drugs in pipeline3 in Phase 3
DrugIndicationStageWatch
daraxonrasibPancreatic CancerPhase 3
daraxonrasib + docetaxelNSCLC (Non-small Cell Lung Cancer)Phase 3
RMC-6236 + Gemcitabine + nab-paclitaxel + Irinotecan + Lipos...Pancreatic CancerPhase 3
RMC-6291 + RMC-6236 + Pembrolizumab + Cisplatin + Carboplati...Non-Small Cell Lung Cancer, NSCLCPhase 1/2
Elironrasib + DaraxonrasibNon-Small Cell Lung Cancer (NSCLC)Phase 1/2

Funding History

4
Total raised:$476M
IPO$275M
Series C$100M
Series B$56M
Series A$45M

Opportunities

Strong positioning in the growing precision oncology market with significant financial resources and focus on targeted therapies.
Active engagement in funding and research opportunities suggests potential for strategic partnerships and platform expansion.

Risk Factors

Clinical-stage company faces typical biotech risks including clinical trial failures, regulatory uncertainties, and competitive pressure.
High valuation creates expectations for strong execution and clinical success.

Competitive Landscape

Operates in the competitive precision oncology space with numerous established pharmaceutical companies and specialized biotechs. Differentiation likely depends on platform capabilities and targeted approach to cancer treatment.